Testing on Humans: How To Predict Hepatotoxicity and Drug Clearance Ahead of Clinical Trials Using Liver-on-a-Chip
Current in vitro approaches for investigational toxicology, drug metabolism (DMPK) and safety are limited and are not fully representative of human response; therefore, drugs showing acceptable preclinical toxicity often fail in human clinical trials, and accurately predicting human drug exposure for new compounds is challenging and costly.
Microphysiological Systems (MPS), or Organ-on-chip (OOC) technologies are a trending way to bridge the gap between traditional DMPK/toxicology assays and human trials by providing more robust and reliable data that translate into clinical outcomes.
CN Bio offers preclinical investigational toxicology and DMPK services using its proprietary, industry-proven PhysioMimix™ OOC technology and liver-on-a-chip model.
In this webinar, we will share our latest advances in investigational toxicology, drug clearance and drug safety, highlighting how the translatable, human-relevant data generated using CN Bio’s liver-on-a-chip model can be used to support (or call into question) the conclusions of internal pre-clinical studies, helping you to make data driven decisions with greater confidence.
Attend this webinar to learn about:
- Developing liver-on-chip MPS systems and comparison to traditional in vitro liver approaches
- Modeling human hepatotoxicity prediction using liver-MPS
- Modeling human drug clearance using liver-MPS
- Data validating and translatability between organ-on-chips and human
- Accessing CN Bio MPS technology
